The observed reduction in mTORC1 activity in the kidney suggests this approach to selective inhibition of mTORC1 may be useful in TSC, LAM, sporadic forms of renal cell carcinoma in which TSC function is lost67, and other forms of cancer that are driven by hyperactivated mTORC1. The gene discussed is TSC1; the disease is renal cell carcinoma.